Advertisement

Topics

BMO Capital Markets Analysts Give Bristol-Myers Squibb (BMY) a $51.00 Price Target

15:18 EST 14 Feb 2018 | Topix

The firm currently has a "sell" rating on the biopharmaceutical company's stock. BMO Capital Markets' price objective indicates a potential downside of 21.62% from the company's previous close.

Original Article: BMO Capital Markets Analysts Give Bristol-Myers Squibb (BMY) a $51.00 Price Target

NEXT ARTICLE

More From BioPortfolio on "BMO Capital Markets Analysts Give Bristol-Myers Squibb (BMY) a $51.00 Price Target"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...